Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer

International Journal of Urology

Volumn 7, Issue 7, 2000, Pages 243-247

  Sumiyoshi, Yoshiteru ^a   Hashine, Katsuyoshi ^a   Nakatsuzi, Hironori ^a   Yamashita, Yokihiko ^a   Karashima, Takashi ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Estramustine phosphate; Etoposide; Hormone refractory; Prostatic tumor

Indexed keywords

ANDROGEN; ANTIANDROGEN; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; LIVER DISEASE; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RELAPSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 0033947227     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2000.00183.x     Document Type: Article

References (18)

1. 1 Jonsson G, Hogberg B, Nilsson T. Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt). Scand. J. Urol. Nephrol. 1977; 11: 231-8.
2. 2 Benson RC, Wear JB, Gill GM. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J. Urol. 1979; 121: 452-4.
3. 3 Iversen P, Rosmussen F, Amussen C et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA Study 9002. J. Urol. 1997; 157: 929-34.
4. 4 Seidmen AD, Scher HI, Petrylak D et al. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol. 1992; 147: 931-4.
5. 5 Colleoni M, Graiff C, Vicario G et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am. J. Clin. Oncol. 1997; 20: 383-6.
6. 6 Hudes GR, Nathan F, Khater C et al. Phase II trial 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 1997; 15: 3156-63.
7. 7 Pienta KJ, Redman BG, Hussain M et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. 1994; 12: 2005-12.
8. 8 Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn. J. Clin. Oncol. 1993; 23: 250-7.
9. 9 Stearns ME, Wang M, Tew KD et al. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J. Cell Biol. 1988; 107: 2647-56.
10. 10 Tew KD, Hartley-Asp B. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urol. Suppl. 1984; 23: 28-33.
11. 11 Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J. Urol. 1993; 149: 1622-5.
12. 12 Dahllof B, Billstorm A, Cabral F et al. Estramustine depolymerizes microtubule by binding to tubuline. Cancer Res. 1993; 53: 4573-81.
13. 13 Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992; 52: 4433-40.
14. 14 Pienta KJ, Redman BG, Bandekar R et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50: 401-7.
15. 15 Dimopoulos MA, Panopoulos C, Bamia C et al. Oral estramustine and oral etoposide for hormone refractory prostate cancer. Urology 1997; 50: 754-8.
16. 16 Vogelzang NJ, Crawford ED, Zeitman A et al. Current clinical trial design issues in hormone-refractory prostate carcinoma. Cancer 1998; 82: 2093-101.
17. 17 Dawson NA. Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer trials. J. Clin. Oncol. 1998; 16: 3398-405.
18. 18 Kelly WK, Scher HI, Mazumdar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 1993; 11: 607-15.